FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310124848> ?p ?o ?g. }

• W4310124848 endingPage "7196" @default.
• W4310124848 startingPage "7195" @default.
• W4310124848 abstract "Introduction Lenalidomide (LEN)-based treatment is standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma (TNE NDMM). The FIRST and SWOG S0777 trials showed safety and efficacy of LEN in TNE NDMM. We present an update to the ongoing, non-interventional, post-authorization MM-034 study (NCT03106324), which assesses the safety of LEN-based treatment (including LEN+dexamethasone [Rd] and Rd+bortezomib [RVd]) or non-LEN treatment (including bortezomib+melphalan/prednisone [VMP]) in patients with TNE NDMM. Methods Patients with TNE NDMM initiating or with < 2 cycles of first-line treatment were eligible. Patients were recruited from 12 countries in Europe and followed for 5 years (≤ 3 years on treatment). Incidence of cardiac events (CEs) was the primary endpoint. Secondary endpoints included safety, infections, and second primary malignancies (SPMs). In this analysis, duration of treatment (DoT), dose adjustments, and Kaplan-Meier estimates for overall survival (OS) were also assessed. Results A total of 452 patients on LEN-based treatment (Rd, 382; RVd, 49) and 440 on non-LEN treatment (VMP, 278) were enrolled. Median (range) follow-up was 20.4 (0.3-50.0) months for LEN (Rd, 20.3 [0.3-50.0]; RVd, 21.4 [1.0-42.0]) and 15.7 (0.2-55.5) months for non-LEN (VMP, 16.1 [0.8-46.6]). In the LEN cohort, 304 (67.3%) patients discontinued treatment, 93 (20.6%) due to adverse events (AEs). In non-LEN, 401 (91.1%) patients discontinued, 69 (15.7%) due to AEs. CEs occurred in 63 (13.9%) patients in LEN and 52 (11.8%) in non-LEN. There was 1 SPM in LEN and 0 in non-LEN. In LEN, 249 (55.1%) patients had ≥ 1 dose adjustment (Rd, 208 [54.5%]; RVd, 33 [67.3%]) vs 260 (59.1%) in non-LEN (VMP, 184 [66.2%]). Median DoT (mDoT) was 10.8 months for LEN (Rd, 10.8; RVd, 11.1) and 8.0 months for non-LEN (VMP, 9.8). In patients with ≥ 1 dose adjustment, mDoT was 15.0 months for LEN (Rd, 15.2; RVd, 11.7) and 9.7 months for non-LEN (VMP, 10.1). In all other patients, mDoT was 4.9 months for LEN (Rd, 4.9; RVd, 4.4) and 5.6 months for non-LEN (VMP, 6.8). Median OS (mOS) (95% confidence interval [CI]) was 41.0 (31.4-not reached [NR]) months in LEN (including Rd and RVd) and 24.8 (22.4-27.8) months in non-LEN (including VMP). In patients who discontinued treatment due to AEs, mOS (95% CI) was 21.9 (20.5-28.7) months in LEN (including Rd and RVd) and 22.1 (18.4-25.6) months in non-LEN (including VMP). In all other patients, mOS (95% CI) was NR in LEN (including Rd and RVd) and 26.9 (23.3-30.5) months in non-LEN (including VMP). Conclusions The safety profile of LEN-based treatment in patients with TNE NDMM was consistent with that previously reported, with no new safety signals identified. More patients in non-LEN discontinued treatment than in LEN. Patients who had ≥ 1 dose adjustment had longer mDoT than those who did not, but this did not account for any differences in disease severity. While the LEN cohort had mOS almost twice that of non-LEN, patients who discontinued LEN due to AEs had a shorter mOS than the entire LEN cohort. Treatment tolerability is an important consideration in improving patient outcomes. Study support This study was supported by Bristol Myers Squibb." @default.
• W4310124848 created "2022-11-30" @default.
• W4310124848 creator A5026010850 @default.
• W4310124848 creator A5026146749 @default.
• W4310124848 creator A5033727268 @default.
• W4310124848 creator A5036440864 @default.
• W4310124848 creator A5051231544 @default.
• W4310124848 creator A5054304877 @default.
• W4310124848 creator A5060490975 @default.
• W4310124848 creator A5071261900 @default.
• W4310124848 creator A5071926851 @default.
• W4310124848 creator A5090001740 @default.
• W4310124848 creator A5091054475 @default.
• W4310124848 date "2022-11-15" @default.
• W4310124848 modified "2023-10-16" @default.
• W4310124848 title "Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study" @default.
• W4310124848 doi "https://doi.org/10.1182/blood-2022-162493" @default.
• W4310124848 hasPublicationYear "2022" @default.
• W4310124848 type Work @default.
• W4310124848 citedByCount "1" @default.
• W4310124848 countsByYear W43101248482023 @default.
• W4310124848 crossrefType "journal-article" @default.
• W4310124848 hasAuthorship W4310124848A5026010850 @default.
• W4310124848 hasAuthorship W4310124848A5026146749 @default.
• W4310124848 hasAuthorship W4310124848A5033727268 @default.
• W4310124848 hasAuthorship W4310124848A5036440864 @default.
• W4310124848 hasAuthorship W4310124848A5051231544 @default.
• W4310124848 hasAuthorship W4310124848A5054304877 @default.
• W4310124848 hasAuthorship W4310124848A5060490975 @default.
• W4310124848 hasAuthorship W4310124848A5071261900 @default.
• W4310124848 hasAuthorship W4310124848A5071926851 @default.
• W4310124848 hasAuthorship W4310124848A5090001740 @default.
• W4310124848 hasAuthorship W4310124848A5091054475 @default.
• W4310124848 hasBestOaLocation W43101248481 @default.
• W4310124848 hasConcept C126322002 @default.
• W4310124848 hasConcept C143998085 @default.
• W4310124848 hasConcept C2776063141 @default.
• W4310124848 hasConcept C2776364478 @default.
• W4310124848 hasConcept C2779609412 @default.
• W4310124848 hasConcept C2780108899 @default.
• W4310124848 hasConcept C2781098529 @default.
• W4310124848 hasConcept C3019894029 @default.
• W4310124848 hasConcept C71924100 @default.
• W4310124848 hasConceptScore W4310124848C126322002 @default.
• W4310124848 hasConceptScore W4310124848C143998085 @default.
• W4310124848 hasConceptScore W4310124848C2776063141 @default.
• W4310124848 hasConceptScore W4310124848C2776364478 @default.
• W4310124848 hasConceptScore W4310124848C2779609412 @default.
• W4310124848 hasConceptScore W4310124848C2780108899 @default.
• W4310124848 hasConceptScore W4310124848C2781098529 @default.
• W4310124848 hasConceptScore W4310124848C3019894029 @default.
• W4310124848 hasConceptScore W4310124848C71924100 @default.
• W4310124848 hasIssue "Supplement 1" @default.
• W4310124848 hasLocation W43101248481 @default.
• W4310124848 hasOpenAccess W4310124848 @default.
• W4310124848 hasPrimaryLocation W43101248481 @default.
• W4310124848 hasRelatedWork W2026021123 @default.
• W4310124848 hasRelatedWork W2041302492 @default.
• W4310124848 hasRelatedWork W2290141854 @default.
• W4310124848 hasRelatedWork W2344741804 @default.
• W4310124848 hasRelatedWork W2911467857 @default.
• W4310124848 hasRelatedWork W2966653498 @default.
• W4310124848 hasRelatedWork W2980809685 @default.
• W4310124848 hasRelatedWork W2988735093 @default.
• W4310124848 hasRelatedWork W3089210822 @default.
• W4310124848 hasRelatedWork W3106536868 @default.
• W4310124848 hasVolume "140" @default.
• W4310124848 isParatext "false" @default.
• W4310124848 isRetracted "false" @default.
• W4310124848 workType "article" @default.